ORXOY Quote, Financials, Valuation and Earnings

BioArctic AB has a net margin of -33.67% compared to Orexo AB's net margin of -65.15%. Orexo AB's return on equity of -134.37% beat BioArctic AB's return on equity of 59.48%.

Orexo AB has a consensus price target of --, signalling downside risk potential of --. On the other hand BioArctic AB has an analysts' consensus of -- which suggests that it could fall by --. Given that Orexo AB has higher upside potential than BioArctic AB, analysts believe Orexo AB is more attractive than BioArctic AB.

Orexo AB has a beta of 0.861, which suggesting that the stock is 13.934% less volatile than S&P 500. In comparison BioArctic AB has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Orexo AB has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioArctic AB offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Orexo AB pays -- of its earnings as a dividend. BioArctic AB pays out -- of its earnings as a dividend.

Orexo AB quarterly revenues are $12.2M, which are smaller than BioArctic AB quarterly revenues of $14M. Orexo AB's net income of -$4.1M is higher than BioArctic AB's net income of -$9.1M. Notably, Orexo AB's price-to-earnings ratio is -- while BioArctic AB's PE ratio is 30.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Orexo AB is 1.31x versus 15.61x for BioArctic AB. Usually stocks with elevated PS ratios are considered overvalued.

Camurus AB has a net margin of -33.67% compared to Orexo AB's net margin of 33.97%. Orexo AB's return on equity of -134.37% beat Camurus AB's return on equity of 21.63%.

Orexo AB has a consensus price target of --, signalling downside risk potential of --. On the other hand Camurus AB has an analysts' consensus of -- which suggests that it could fall by --. Given that Orexo AB has higher upside potential than Camurus AB, analysts believe Orexo AB is more attractive than Camurus AB.

Orexo AB has a beta of 0.861, which suggesting that the stock is 13.934% less volatile than S&P 500. In comparison Camurus AB has a beta of 0.933, suggesting its less volatile than the S&P 500 by 6.658%.

Orexo AB has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Camurus AB offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Orexo AB pays -- of its earnings as a dividend. Camurus AB pays out -- of its earnings as a dividend.

Orexo AB quarterly revenues are $12.2M, which are smaller than Camurus AB quarterly revenues of $59.6M. Orexo AB's net income of -$4.1M is lower than Camurus AB's net income of $20.2M. Notably, Orexo AB's price-to-earnings ratio is -- while Camurus AB's PE ratio is 49.63x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Orexo AB is 1.31x versus 16.54x for Camurus AB. Usually stocks with elevated PS ratios are considered overvalued.

Hansa Biopharma AB has a net margin of -33.67% compared to Orexo AB's net margin of -481.29%. Orexo AB's return on equity of -134.37% beat Hansa Biopharma AB's return on equity of --.

Orexo AB has a consensus price target of --, signalling downside risk potential of --. On the other hand Hansa Biopharma AB has an analysts' consensus of -- which suggests that it could fall by --. Given that Orexo AB has higher upside potential than Hansa Biopharma AB, analysts believe Orexo AB is more attractive than Hansa Biopharma AB.

Orexo AB has a beta of 0.861, which suggesting that the stock is 13.934% less volatile than S&P 500. In comparison Hansa Biopharma AB has a beta of 0.402, suggesting its less volatile than the S&P 500 by 59.764%.

Orexo AB has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Hansa Biopharma AB offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Orexo AB pays -- of its earnings as a dividend. Hansa Biopharma AB pays out -- of its earnings as a dividend.

Orexo AB quarterly revenues are $12.2M, which are larger than Hansa Biopharma AB quarterly revenues of $3.2M. Orexo AB's net income of -$4.1M is higher than Hansa Biopharma AB's net income of -$15.6M. Notably, Orexo AB's price-to-earnings ratio is -- while Hansa Biopharma AB's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Orexo AB is 1.31x versus 12.08x for Hansa Biopharma AB. Usually stocks with elevated PS ratios are considered overvalued.

Vivesto AB has a net margin of -33.67% compared to Orexo AB's net margin of --. Orexo AB's return on equity of -134.37% beat Vivesto AB's return on equity of -23.44%.

Orexo AB has a consensus price target of --, signalling downside risk potential of --. On the other hand Vivesto AB has an analysts' consensus of -- which suggests that it could fall by --. Given that Orexo AB has higher upside potential than Vivesto AB, analysts believe Orexo AB is more attractive than Vivesto AB.

Orexo AB has a beta of 0.861, which suggesting that the stock is 13.934% less volatile than S&P 500. In comparison Vivesto AB has a beta of 32.470, suggesting its more volatile than the S&P 500 by 3147.007%.

Orexo AB has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vivesto AB offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Orexo AB pays -- of its earnings as a dividend. Vivesto AB pays out -- of its earnings as a dividend.

Orexo AB quarterly revenues are $12.2M, which are larger than Vivesto AB quarterly revenues of --. Orexo AB's net income of -$4.1M is lower than Vivesto AB's net income of -$755.6K. Notably, Orexo AB's price-to-earnings ratio is -- while Vivesto AB's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Orexo AB is 1.31x versus -- for Vivesto AB. Usually stocks with elevated PS ratios are considered overvalued.